UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 202

Sortiert nach

Syrosingopine sensitizes cancer cells to killing by metformin

Science advances, 2016-12, Vol.2 (12), p.e1601756-e1601756

2016

Volltextzugriff (PDF)

Building Rule of Law in the Arab World: Tunisia, Egypt, and Beyond

1, 2015

Volltextzugriff (PDF)

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

Oncotarget, 2020-02, Vol.11 (8), p.759-774

2020

Volltextzugriff (PDF)

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Frontiers in oncology, 2024-08, Vol.14

2024

Volltextzugriff (PDF)

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ⁷¹⁶ mice

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (36), p.13544-13549

2008

Volltextzugriff (PDF)

Research and innovation in the development of everolimus for oncology

Expert opinion on drug discovery, 2011-03, Vol.6 (3), p.323-338

2011

Volltextzugriff (PDF)

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

Translational oncology, 2010-08, Vol.3 (4), p.264,IN6-275,IN7

2010

Volltextzugriff (PDF)

Inhibition of the mTORC1 Pathway Suppresses Intestinal Polyp Formation and Reduces Mortality in $Apc^{\Delta 716}$ Mice

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (36), p.13544-13549

2008

Volltextzugriff (PDF)

Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2058-2058

2023

Volltextzugriff (PDF)

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.421-421

2020

Volltextzugriff (PDF)

Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2044-2044

2023

Volltextzugriff (PDF)

Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3118-3118

2021

Volltextzugriff (PDF)

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2068-TPS2068

2021

Volltextzugriff (PDF)

The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERα Pathway in Breast Cancer

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (10), p.3743-3751

2008

Volltextzugriff (PDF)

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C096-C096

2019

Volltextzugriff (PDF)

Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.831-831

2014

Volltextzugriff (PDF)

AEE788

Cancer research (Chicago, Ill.), 2004-07, Vol.64 (14), p.4931-4941

2004

Volltextzugriff (PDF)

Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2529-2529

2018

Volltextzugriff (PDF)

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2530-2530

2018

Volltextzugriff (PDF)

Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5645-5645

2022

Volltextzugriff (PDF)

Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5646-5646

2022

Volltextzugriff (PDF)

Phase 1/2a trial of daily oral BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2532-2532

2017

Volltextzugriff (PDF)

A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS2602-TPS2602

2017

Volltextzugriff (PDF)

Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2525-2525

2016

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(193)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Syrosingopine sensitizes cancer cells to killing by metformin

Building Rule of Law in the Arab World: Tunisia, Egypt, and Beyond

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ⁷¹⁶ mice

Research and innovation in the development of everolimus for oncology

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

Inhibition of the mTORC1 Pathway Suppresses Intestinal Polyp Formation and Reduces Mortality in $Apc^{\Delta 716}$ Mice

Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601)

The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR

Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers

Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma

The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERα Pathway in Breast Cancer

Abstract C096: Modeling the clinical paradigm of lisavanbulin (BAL101553) deployment in patient-derived xenografts (PDX) of glioblastoma (GBM)

Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab

AEE788

Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors

Abstract 5645: BAL0891: A novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity

Abstract 5646: BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division

Phase 1/2a trial of daily oral BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors

A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma

A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors

Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors

Aktive Filter

Suchergebnisse filtern